Drug intelligence / Profile preview

3-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1H-inden-1-one

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules

Overview

3-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1H-inden-1-one is a synthetic small molecule belonging to the indene class of organic compounds, characterized by an indene moiety fused with various functional groups. It has been studied as a ligand for estrogen receptors, particularly showing high potency and moderate selectivity for estrogen receptor beta (ERβ) over alpha (ERα). Structural studies have confirmed its binding to ERβ, suggesting potential utility in modulating estrogen receptor activity. The compound is considered experimental and has not been approved for clinical use or advanced beyond preclinical research[1][2][6].

Other names: 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE

Targets

ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on 3-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1H-inden-1-one.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1H-inden-1-one.

Explore the full profile